Generic GCP slides do not cause protocol deviations. Misunderstood eligibility criteria and missed pharmacokinetic sampling windows do. That distinction is the entire argument of Christine Senn’s framework for what the live site initiation visit should actually contain, published by Advarra this week as Part 2 of a three-part series on SIV training design.
The practical problem is crowding. When a live SIV carries standard regulatory text, vendor screenshots, and broad documentation reminders alongside study-specific content, the specific content loses attention. Senn’s principle is simple: protect live time for material that varies by study, creates operational risk, or requires real-time discussion between the sponsor, CRO, and site. That means eligibility interpretation (not just what the criteria say, but where screen failures are likely and which questions need escalation before enrollment), investigational product handling specific to this protocol, disease-specific outcome measures that are time-sensitive or subjective, and lab or imaging workflows where a missed sample or rejected image creates missing data or a protocol deviation. Sponsor-specific safety thresholds and cohort governance rules belong there too, distinct from general adverse event reporting principles, which can be trained once and reused.
The oncology section makes the sharpest point. Oncology trials typically carry layered eligibility, biopsy requirements, central lab and imaging workflows, dose-escalation governance, and protocol-specific adverse events of special interest. The instinct is to build a longer SIV. Senn argues the opposite: complex studies need more focused live discussion, not more generic content on top. The Advarra Site-Sponsor Consortium, which launched in February 2022 with more than 20 research sites, life sciences companies, and standards bodies, will release a white paper this fall on competency-based, role-based, and reusable training models aligned with international regulatory guidelines, including the ICH E6(R3) framework, which supports proportionate, risk-based approaches to trial conduct. The SIV redesign Senn describes is one piece of that larger structure.
A four-question test she offers gives sponsors and CROs a practical filter before building slide decks: does this topic vary by protocol, would misunderstanding it create meaningful risk, does it require live discussion or role clarification, and can it be replaced by a reusable module? Content that clears any of those bars belongs in the SIV. Content that clears none of them consumes the attention that eligibility and dosing specifics actually need. The signal to watch is whether the fall white paper translates this content filter into a training-design standard that sponsors can apply at the protocol level.
Source link: https://www.advarra.com/blog/what-actually-belongs-in-the-live-siv/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
